Semin Thromb Hemost 2000; Volume 26(Number s1): 061-068
DOI: 10.1055/s-2000-9495
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Low-Molecular-Weight Heparin in the Treatment of Venous Thromboembolism

Russell D. Hull, Graham F. Pineo
  • University of Calgary, Calgary, Alberta, Canada
Further Information

Publication History

Publication Date:
31 December 2000 (online)

 

ABSTRACT

The low-molecular-weight heparins (LMWHs) have been evaluated in the prevention and treatment of deep-vein thrombosis and pulmonary embolism. LMWHs have been found to be safe and effective in this clinical setting and have advantages over unfractionated heparin. These advantages include less serious and less frequent therapeutic complications. The favorable pharmacokinetic profile of LMWHs compared with heparin has allowed for safe, effective, and convenient treatment of patients with venous thromboembolism. Use of LMWHs ultimately results in considerable cost savings for the health care system.

KEYWORD

Low-molecular-weight heparin - tinzaparin - thromboprophylaxis - venous thromboembolism - cost-effectiveness

REFERENCES

  • 1 Brandjes D P, Buller H R, Heijboer H. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis.  Lancet . 1997;  349 759-762
    CrossrefPubMedSearch in Google Scholar
  • 2 Franzeck U K, Schalch I, Jager K A. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study).  Circulation . 1996;  93 74-79
    PubMedSearch in Google Scholar
  • 3 Lane D A. Heparin binding and neutralizing protein. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications London: Edward Arnold, 1989: 363-931
    Search in Google Scholar
  • 4 Lindahl U, Thunberg L, Backstrom G. Extension and structural variability of the antithrombin-binding sequence in heparin.  J Biol Chem . 1984;  259 12368-12376
    PubMedSearch in Google Scholar
  • 5 Rosenberg R D, Lam L. Correlation between structure and function of heparin.  Proc Natl Acad Sci USA . 1979;  76 1218-1222
    PubMedSearch in Google Scholar
  • 6 Salzman E W, Rosenberg R D, Smith M H, Lindon J N, Favreau L. Effect of heparin and heparin fractions on platelet aggregation.  J Clin Invest . 1980;  65 64-73
    CrossrefPubMedSearch in Google Scholar
  • 7 Casu B, Oreste P, Torri G. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies.  Biochem J . 1981;  197 599-609
    PubMedSearch in Google Scholar
  • 8 Weitz J I, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.  J Clin Invest . 1990;  86 385-391
    CrossrefPubMedSearch in Google Scholar
  • 9 Tollefsen D M, Majerus D W, Blank M K. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma.  J Biol Chem . 1982;  257 2162-2169
    PubMedSearch in Google Scholar
  • 10 Hoppensteadt D A, Walenga J M, Fasanella A, Jeske W, Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.  Thromb Res . 1995;  77 175-185
    CrossrefPubMedSearch in Google Scholar
  • 11 Blajchman M A, Young E, Ofosu F A. Effects of unfractionated heparin, dermatan sulfate and low molecular weight heparin on vessel wall permeability in rabbits.  Ann N Y Acad Sci . 1989;  556 245-254
    PubMedSearch in Google Scholar
  • 12 Gallus A, Jackaman J, Tillett J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism.  Lancet . 1986;  2 1293-1296
    PubMedSearch in Google Scholar
  • 13 Hull R D, Raskob G E, Rosenbloom D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis.  N Engl J Med . 1990;  322 1260-1264
    PubMedSearch in Google Scholar
  • 14 Hyers T M, Agnelli G, Hull R D. Antithrombotic therapy for venous thromboembolic disease.  Chest . 1998;  14(5 suppl) 561S-578S
    PubMedSearch in Google Scholar
  • 15 Hull R D, Raskob G E, Rosenbloom D. Optimal therapeutic level of heparin therapy in patients with venous thrombosis.  Arch Intern Med . 1992;  152 1589-1595
    CrossrefPubMedSearch in Google Scholar
  • 16 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. Relation between the time to achieve the lower limit of the aPTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.  Arch Intern Med . 1997;  157 2562-2568
    CrossrefPubMedSearch in Google Scholar
  • 17 Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A. The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.  Arch Intern Med . 1997;  157 2317-2321
    CrossrefPubMedSearch in Google Scholar
  • 18 Anand S, Ginsberg J S, Kearon C, Gent M, Hirsh J. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.  Arch Intern Med . 1996;  156 1677-1681
    CrossrefPubMedSearch in Google Scholar
  • 19 Campbell N R, Hull R D, Brant R. Aging and heparin-related bleeding.  Arch Intern Med . 1996;  156 857-860
    CrossrefPubMedSearch in Google Scholar
  • 20 White R H, Zhou H, Woo L, Mungall D. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements.  Arch Intern Med . 1997;  157 2468-2472
    CrossrefPubMedSearch in Google Scholar
  • 21 Fennerty A, Thomas P, Backhouse G. Audit of control of heparin treatment.  BMJ . 1985;  290 27-28
    PubMedSearch in Google Scholar
  • 22 Wheeler A P, Jaquiss R D, Newman J H. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis.  Arch Intern Med . 1988;  148 1321-1325
    CrossrefPubMedSearch in Google Scholar
  • 23 Raschke R A, Reilly B M, Guidry J R, Fontana J R, Srinivas S. The weight-based heparin dosing nomogram compared with a ``standard care'' nomogram.  Ann Intern Med . 1993;  119 874-881
    CrossrefPubMedSearch in Google Scholar
  • 24 Hirsh J, Warkentin T E, Raschke R. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.  Chest . 1998;  114(5 suppl) 489S-510S
    PubMedSearch in Google Scholar
  • 25 Kelton J G. Heparin-induced thrombocytopenia.  Haemostasis . 1986;  16 173-186
    PubMedSearch in Google Scholar
  • 26 Greinacher A, Michel I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia.  Thromb Haemost . 1991;  66 734-736
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Boshkov L K, Warkentin T E, Hayward C P, Andrew M, Kelton J G. Heparin-induced thrombocytopenia and thrombosis: Clinical and laboratory studies.  Br J Haematol . 1993;  84 322-328
    PubMedSearch in Google Scholar
  • 28 Magnani H N. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran.  Thromb Haemost . 1993;  70 554-561
    PubMedSearch in Google Scholar
  • 29 Arepally G, Reynolds C, Tomaski A. Comparison of PF4/heparin ELISA assay with the (14C) serotonin release assay in the diagnosis of heparin-induced thrombocytopenia.  Am J Clin Pathol . 1995;  104 648-654
    PubMedSearch in Google Scholar
  • 30 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1330-1335
    CrossrefPubMedSearch in Google Scholar
  • 31 Warkentin T E, Chong B H, Greinacher A. Heparin-induced thrombocytopenia: Towards consensus.  Thromb Haemost . 1998;  79 1-7
    Thieme ConnectPubMedSearch in Google Scholar
  • 32 Hull R D, Raskob G E, Pineo G F. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis.  N Engl J Med . 1992;  326 975-982
    CrossrefPubMedSearch in Google Scholar
  • 33 Greinacher A, Volpel H, Janssens U. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study.  Circulation . 1999;  99 73-80
    CrossrefPubMedSearch in Google Scholar
  • 34 Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor.  Br J Haematol . 1992;  82 627-629
    PubMedSearch in Google Scholar
  • 35 Hirsh J, Levine M N. Low molecular weight heparin.  Blood . 1992;  79 1-17
    PubMedSearch in Google Scholar
  • 36 Fareed J, Walenga J M, Hoppensteadt D, Huan X, Racanelli A. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins.  Haemostasis . 1988;  18(suppl 3) 3-15
    PubMedSearch in Google Scholar
  • 37 Bara L, Samama M. Pharmacokinetics of low molecular weight heparins.  Acta Chir Scand . 1988;  543 65-72
    PubMedSearch in Google Scholar
  • 38 Briant L, Caranobe C, Saivin S. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.  Thromb Haemost . 1989;  61 348-353
    PubMedSearch in Google Scholar
  • 39 Andersson L O, Barrowcliffe T W, Holmer E, Johnson E A, Soderstrom G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma.  Thromb Res . 1979;  15 531-541
    CrossrefPubMedSearch in Google Scholar
  • 40 Fareed J, Walenga J M, Racanelli A. Validity of the newly established low-molecular-weight heparin standard in cross-referencing low-molecular-weight heparins.  Haemostasis . 1988;  18(suppl) 33-47
    PubMedSearch in Google Scholar
  • 41 Barrowcliffe T W, Curtis A D, Johnson E A, Thomas D P. An international standard for low molecular weight heparin.  Thromb Haemost . 1988;  60 1-7
    PubMedSearch in Google Scholar
  • 42 Holmer E, Soderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives: Anticoagulant and antithrombotic properties.  Haemostastis . 1986;  16(suppl 2) 1-7
    PubMedSearch in Google Scholar
  • 43 Carter C J, Kelton J G, Hirsh J. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits.  Blood . 1982;  59 1239-1245
    PubMedSearch in Google Scholar
  • 44 Cade J F, Buchanan M R, Boneu B. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation.  Thromb Res . 1984;  35 613-625
    CrossrefPubMedSearch in Google Scholar
  • 45 Andriuoli G, Mastacchi R, Barbanti M, Sarret M. Comparison of the antithrombotic and haemorrhagic effects of heparin and a new low molecular weight heparin in rats.  Haemostasis . 1985;  15 324-330
    PubMedSearch in Google Scholar
  • 46 Lensing A W, Prins M H, Davidson B L, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis.  Arch Intern Med . 1995;  155 601-607
    CrossrefPubMedSearch in Google Scholar
  • 47 Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A. Adverse effects of three different forms of heparin therapy: Thrombocytopenia, increased transaminases, and hyperkalaemia.  Eur J Clin Pharmacol . 1989;  37 415-418
    CrossrefPubMedSearch in Google Scholar
  • 48 Monreal M, Vinas L, Monreal L. Heparin-related osteoporosis in rats. A comparative study between unfractionated heparin and a low-molecular-weight heparin.  Haemostasis . 1990;  20 204-207
    PubMedSearch in Google Scholar
  • 49 Matzsch T, Bergqvist D, Hedner U, Nilsson B, Ostergaard P. Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats.  Thromb Haemost . 1990;  63 505-509
    PubMedSearch in Google Scholar
  • 50 Shaughnessy S G, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria.  Blood . 1995;  86 1368-1373
    PubMedSearch in Google Scholar
  • 51 Warkentin T E, Levine M N, Hirsh J. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.  N Engl J Med . 1995;  332 1374-1376
    PubMedSearch in Google Scholar
  • 52 Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound.  Thromb Res . 1984;  34 557-560
    CrossrefPubMedSearch in Google Scholar
  • 53 Omri A, Delaloye F J, Andersen H, Bachmann F. Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy.  Thromb Haemost . 1989;  61 55-56
    PubMedSearch in Google Scholar
  • 54 Wahlberg T B, Kher A. Low molecular weight heparin as thromboprophylaxis in pregnancy. A retrospective analysis from 14 European clinics.  Haemostasis . 1994;  24 55-56
    PubMedSearch in Google Scholar
  • 55 Dulitzki M, Pauzner R, Langevitz P. Low-molecular-weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies.  Obstet Gynecol . 1996;  87 380-383
    CrossrefPubMedSearch in Google Scholar
  • 56 Nelson-Piercy C, Letsky E A, De Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk.  Am J Obstet Gynecol. 1997;  176 1062-1068
    CrossrefPubMedSearch in Google Scholar
  • 57 Hunt B J, Doughty H A, Majumdar G. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies.  Thromb Haemost . 1997;  77 39-43
    PubMedSearch in Google Scholar
  • 58 Sanson B J, Lensing A W, Prins M H. Safety of low-molecular-weight heparin in pregnancy: A systematic review.  Thromb Haemost . 1999;  81 668-672
    PubMedSearch in Google Scholar
  • 59 Ginsberg J S, Hirsh J. Use of antithrombotic agents during pregnancy.  Chest . 1998;  114(5 suppl) 524S-530S
    PubMedSearch in Google Scholar
  • 60 Bratt G, Tornebohm E, Granqvist S, Aberg W, Lockner D. A comparison between low molecular weight heparin (KABI 2165) standard heparin in the intravenous treatment of deep venous thrombosis.  Thromb Haemost. 1985;  54 813-817
    PubMedSearch in Google Scholar
  • 61 Holm H A, Ly B, Handeland G F. Subcutaneous heparin treatment of deep venous thrombosis: A comparison of unfractionated low molecular weight heparin.  Haemostasis. 1986;  16(suppl 2) 30-37
    PubMedSearch in Google Scholar
  • 62 Albada J, Nieuwenhuis H K, Sixma J J. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin): Results of a double-blind randomized study.  Circulation . 1989;  80 935-940
    PubMedSearch in Google Scholar
  • 63 Bratt G, Aberg W, Johansson M. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (deep vein thrombosis).  Thromb Haemost . 1990;  64 506-510
    PubMedSearch in Google Scholar
  • 64 Harenberg J, Huck K, Bratsch H. Therapeutic application of subcutaneous low-molecular-weight heparin in acute venous thrombosis.  Haemostasis . 1990;  20(suppl 1) 205-219
    PubMedSearch in Google Scholar
  • 65 Siegbahn A, Y-Hassan S, Boberg J. Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo.  Thromb Res . 1989;  55 767-778
    CrossrefPubMedSearch in Google Scholar
  • 66 Prandoni P, Lensing A W, Buller H R. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis.  Lancet . 1992;  339 441-445
    CrossrefPubMedSearch in Google Scholar
  • 67 Lopaciuk S, Meissner A J, Filipecki S. Subcutaneous low molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep vein thrombosis: A Polish multicenter trial.  Thromb Haemost . 1992;  68 14-18
    PubMedSearch in Google Scholar
  • 68 Simonneau G, Charbonnier B, Decousus H. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis.  Arch Intern Med . 1993;  153 1541-1546
    CrossrefPubMedSearch in Google Scholar
  • 69 Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis.  Thromb Haemost . 1994;  72 186-190
    PubMedSearch in Google Scholar
  • 70 Levine M, Gent M, Hirsh J. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.  N Engl J Med . 1996;  334 677-681
    CrossrefPubMedSearch in Google Scholar
  • 71 Koopman M MW, Prandoni P, Piovella F. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.  N Engl J Med . 1996;  334 682-687
    CrossrefPubMedSearch in Google Scholar
  • 72 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.  N Engl J Med . 1997;  337 657-662
    CrossrefPubMedSearch in Google Scholar
  • 73 Simonneau G, Sors H, Charbonnier B. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism.  N Engl J Med . 1997;  337 663-669
    CrossrefPubMedSearch in Google Scholar
  • 74 Decousus H, Leizorovicz A, Parent F. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis.  New Engl J Med . 1998;  338 409-415
    CrossrefPubMedSearch in Google Scholar
  • 75 Hettiarchichi R JK, Prins M H, Lensing A W, Buller H R. Low molecular weight heparin versus unfractionated heparin in the initial treatment of venous thromboembolism.  Curr Opin Pulm Med . 1998;  4 220-225
    PubMedSearch in Google Scholar
  • 76 Green D, Hull R D, Brant R, Pineo G F. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.  Lancet . 1992;  339 1476 ((Letter))
    PubMedSearch in Google Scholar
  • 77 Hull R D, Raskob G E, Rosenbloom D. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective.  Arch Intern Med . 1997;  157 289-294
    CrossrefPubMedSearch in Google Scholar
  • 78 van den Belt G A, Bossuyt P M, Prins M H, Gallus A S, Buller H R, for the TASMAN Study Group. Replacing in-patient care by out-patient care in the treatment of deep venous thrombosis-an economic evaluation.  Thromb Haemost . 1998;  79 259-263
    PubMedSearch in Google Scholar
  • 79 Wells P S, Kovacs M J, Bormanis J. Expanding eligibility for out-patient treatment of deep venous thrombosis pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection.  Arch Intern Med . 1998;  158 1809-1812
    CrossrefPubMedSearch in Google Scholar
  • 80 Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of out-patient treatment of deep-vein thrombosis with low-molecular-weight heparin.  Arch Intern Med . 1998;  158 2001-2003
    CrossrefPubMedSearch in Google Scholar
  • 81 Savage K J, Wells P S, Schulz V. Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity.  Thromb Haemost . 1999;  82 1008-1010
    PubMedSearch in Google Scholar
  • 82 Hull R D, Raskob G E, Brant R F. Low-molecular-weight heparin versus heparin in the treatment of patients with pulmonary embolism.  Arch Intern Med . 2000;  160 229-236
    CrossrefPubMedSearch in Google Scholar
  • 83 Fiessinger J N, Lopez-Fernandez M, Gatterer E. Once-daily subcutaneous dalteparin, a low molecular weight heparin for the initial treatment of acute deep vein thrombosis.  Thromb Haemost. 1996;  76 195-199
    PubMedSearch in Google Scholar
  • 84 Spiro T E. Clinical use of low molecular weight heparins.  Thromb Haemost . 1997;  1527 373
    PubMedSearch in Google Scholar
  • 85 Charbonnier B A, Fiessinger J N, Banga J D. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis.  Thromb Haemost . 1998;  79 897-901
    PubMedSearch in Google Scholar